Applied Evidence

It’s time to rethink your approach to C diff infection

Author and Disclosure Information

 

References

CASE 2: Ms. Z has several risk factors for recurrent CDI and has an elevated WBC count and SCr level (WBC ≥ 15,000 and SCr > 1.5 mg/dL). Thus, she is classified as having severe, recurrent CDI. Oral levofloxacin and metronidazole should be discontinued, because they increase the risk for treatment failure and development of more virulent CDI strains, such as BI/NAP1/027. Since Ms. Z used metronidazole for treatment of her initial CDI, vancomycin or fidaxomicin should be used at this time. Either vancomycin PO 125 mg qid for 10 days or fidaxomicin 200 mg bid for 10 days would be an appropriate regimen; however, because of cost and unknown insurance coverage, vancomycin is the most appropriate regimen.

CORRESPONDENCE
Jeremy Vandiver, PharmD, BCPS, University of Wyoming School of Pharmacy, Saint Joseph Family Medicine Residency, 1000 E. University Avenue, Dept 3375, Laramie, WY 82071; jvandive@uwyo.edu

Pages

Recommended Reading

Hep C sofosbuvir/daclatasvir combo promising for COVID-19
MDedge Family Medicine
About one-third of older Americans receive shingles vaccine
MDedge Family Medicine
Wave, surge, or tsunami
MDedge Family Medicine
Six snags docs hit when seeing patients again
MDedge Family Medicine
COVID-19 symptoms can linger for months
MDedge Family Medicine
COVID-19: A primary care perspective
MDedge Family Medicine
Zika virus syndrome may adversely affect children normocephalic at birth
MDedge Family Medicine
Proton pump inhibitors tied to COVID-19 risk
MDedge Family Medicine
Why doctors keep monitoring kids who recover from mysterious COVID-linked illness
MDedge Family Medicine
Schools can reopen safely with precautions, experts say
MDedge Family Medicine